TrialOral oncology2021

Palbociclib and cetuximab in cetuximab-resistant human papillomavirus-related oropharynx squamous-cell carcinoma: A multicenter phase 2 trial.

Peter Oppelt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.